stockrow10x Genomics
TXG Healthcare Medical Devices
10x Genomics' revenue for fiscal 2025 (year ended December 2025) was $642.8 million, up 5.25% from fiscal 2024.
- Revenue
- +1.12%
- EPS
- +31.8%
- Free cash flow
- −4.61%
Quarter to September 2026, against a year earlier
Follow TXG
Alert me
10x Genomics (TXG) Free cash flow
10x Genomics's free cash flow for fiscal 2025 was $130.1M, compared with −$6.7M in fiscal 2024. Over the twelve months to 30 September 2026 it was $93.8M. Over the past ten years it has ranged from −$256.3M (fiscal 2020) to $130.1M (fiscal 2025) — the current reading is the highest in ten years. Free cash flow has risen for 3 consecutive fiscal years. 10x Genomics ranks 21st of 149 Medical Devices companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $130.1M | — |
| FY2024 | −$6.7M | — |
| FY2023 | −$64.7M | — |
| FY2022 | −$165.3M | — |
| FY2021 | −$122.7M | — |
| FY2020 | −$256.3M | — |
| FY2019 | −$8.1M | — |
| FY2018 | −$83.1M | — |
| FY2017 | −$14.5M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | $14.9M | (3.41%) |
| Jun 2026 | $15.4M | (37.26%) |
| Mar 2026 | $24.5M | (37.12%) |
| Dec 2025 | $39.0M | (8.29%) |
| 29 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| SNN Smith & Nephew SNATS, Inc. compare | $2.0B |
| GMED Globus Medical, Inc. compare | $766.6M |
| BIO.B Bio-Rad Laboratories, Inc. compare | $468.1M |
| BIO Bio-Rad Laboratories, Inc. compare | $468.1M |
| HAE Haemonetics Corporation compare | $344.9M |
| PODD Insulet Corporation compare | $260.0M |
| BRKR Bruker Corporation compare | $244.7M |
| PEN Penumbra, Inc. compare | $200.3M |
| TXG 10x Genomics | $121.4M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on TXG
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement